3 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $86000 | -$47M | 0.0% | -27661.6% | -$13M | — | $15M |
| 2024 | $12000 | -$18M | 0.0% | -250341.7% | -$16M | — | $6M |
| 2023 | — | -$49M | — | — | -$11M | — | $22M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$4M | — | — | -$2M | — | $74M |
| Dec '25 | — | -$7M | — | — | -$5M | — | $69M |
| Sep '25 | — | -$6M | — | — | -$9M | — | $73M |
| Jun '25 | — | -$32M | — | — | -$1M | — | $15M |
| Mar '25 | $0 | -$4M | — | — | -$3M | — | $7M |
| Dec '24 | $12000 | -$6M | 0.0% | -41700.0% | — | $4M | $2M |
| Sep '24 | $74000 | -$5M | 0.0% | -8451.4% | — | — | $4M |
| Jun '24 | — | -$6M | — | — | -$4M | — | $6M |
| Mar '24 | — | -$6M | — | — | -$4M | — | $9M |
| Dec '23 | — | -$5M | — | — | -$2M | — | $15M |
| Sep '23 | — | -$726000 | — | — | -$6M | — | — |
| Jun '23 | — | -$4M | — | — | -$3M | — | $22M |
| Mar '23 | — | -$4M | — | — | -$3M | — | — |
| Dec '22 | — | -$3M | — | — | — | — | — |
How the market has priced IXHL against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 2 years, Incannex Healthcare Inc.'s revenue has grown 616.7% per year. These are computed facts, not advice.
As of FY2025, Incannex Healthcare Inc. reported — of total debt against $15M of cash; operating income covered interest expense -78.5×.
In FY2025, gross margin was —, operating margin -27661.6%, and net margin -54517.4%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.